NCT00458575View on ClinicalTrials.gov

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Retinitis Pigmentosa
Interventions
DRUG

CNTO 2476

Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.

Trial Locations (3)

Unknown

Miami

Southwest Portland

Dallas

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY